Navigation Links
Groundbreaking Consensus Statement Provides a Road Map for Treating Melanoma Patients with Cancer Immunotherapy
Date:8/27/2013

Milwaukee, WI (PRWEB) August 27, 2013

The first evidence-based consensus statement on tumor immunotherapy for the treatment of patients with melanoma has been released by the Society for Immunotherapy of Cancer (SITC) and published online by Nature Reviews Clinical Oncology. Essentially a road map for using immunotherapy to treat patients with melanoma, this consensus statement known as the “Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma,” provides patients and physicians alike with expert evidence-based recommendations for the use of different immunotherapies including interferon-a2, pegylated interferon, interleukin-2 (IL-2) and ipilimumab. Recommendations for patient selection, toxicity management, clinical end points, and sequencing or combination of therapy, are also provided in this statement.

“Cancer immunotherapy is a rapidly advancing form of cancer treatment that has induced durable therapeutic responses in a subset of patients with advanced melanoma,” Michael Atkins, MD, Georgetown-Lombardi Comprehensive Cancer Center and a co-author on the paper said. “Current data suggests that cancer immunotherapy is being underutilized and many patients who might benefit from immunotherapy are not given the opportunity in the optimal setting. The goal of these guidelines is to change that and to provide a readily available and comprehensive resource about how and when to consider immunotherapy for patients with melanoma.”

Prior to the consensus statement’s publication, the lack of evidence-based guidelines in the field created obstacles and discord for practicing oncologists in the treatment of patients with melanoma. Now, this statement provides the best available evidence and consensus thinking for those interested in pursuing treatment with immunotherapy.

“The SITC consensus statement addresses the knowledge gaps and creates a standard set of guiding principles for oncologists set forth for the effective and efficient application of cancer immunotherapy for patients with melanoma,” Howard L. Kaufman, MD, FACS, Rush University Medical Center and corresponding author on the paper said. “The group of authors who developed this statement considered the strength of the evidence for key issues in the field and provided consensus recommendations in these areas; especially where data was weak or missing.”

This consensus statement was created from work done by the SITC Cancer Immunotherapy Guidelines (CIG) Task Force established in 2010 and made up of more than 30 experts in the field of melanoma. The task force utilized the 2011 Institute of Medicine’s “Standards for Developing Trustworthy Clinical Practice Guidelines” to assure a fair, transparent and balanced process for the consensus statement. However, as cancer immunotherapy continues to rapidly develop, the SITC Melanoma CIG Task Force will update the consensus statement as new findings and results from on-going clinical trials or as the approval of drugs from the FDA for the treatment of melanoma are released.

To read “The Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma,” visit: http://www.nature.com/nrclinonc/journal/vaop/ncurrent/full/nrclinonc.2013.153.html.

For more information on the consensus statement and the Society for Immunotherapy of Cancer, visit: http://www.sitcancer.org/about-sitc/initiatives/cancer-immunotherapy-guidelines.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11066759.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Groundbreaking Nigeria summit results in major commitment to reduce child deaths
2. IU researchers interview pro-anorexic bloggers for groundbreaking new study
3. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
4. Groundbreaking clinical trial looks at fecal transplant as treatment for C. difficile
5. FEMA awards $1 Million to WPI to develop groundbreaking toxic gas sensors for firefighters
6. JTCC researchers play important role in groundbreaking study that may change transplant practices
7. MyPuress Releases Details About Groundbreaking New Product
8. Rectal microbicide research takes giant leap forward with groundbreaking educational video
9. Skin Authority Creates One-of-a-Kind Solution for the One Billion People Worldwide Who are Vitamin D Deficient -- Groundbreaking Launch of "Inside Out" System
10. Groundbreaking Training Video Prepares Surgical Team to Become Safest in the U.S.
11. Groundbreaking UK study shows key enzyme missing from aggressive form of breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in post-acute health care, have expanded their existing home health joint venture through ... AccentCare has been operating a joint venture home health company with Asante, delivering ...
Breaking Medicine News(10 mins):
(Date:9/13/2017)... , Sept. 13, 2017   OrthoAtlanta has been ... Atlanta Football Host Committee (AFHC) for the 2018 College Football ... 8, 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... the AFHC "I,m In" campaign, participating in many activities leading ... ...
(Date:9/12/2017)... , Sept. 12, 2017  Consumer reviews on the independent review ... as the number one company for hearing aids, ranking it higher ... other brands. ... Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high performance, state-of-the-art, ...
(Date:9/9/2017)... 8, 2017 ... Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, September 18 th .The ... free MRI brain scans to the public.Where:  BTF,s ... at 501 K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the ...
Breaking Medicine Technology: